Skip to content
  • News
  • Anal Cancer
  • Bladder Cancer
  • Bone Cancer
  • Brain Cancer
  • Breast Cancer
  • Cancer of Unknown Primary
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • GIST
  • Head & Neck Cancer
  • Hodgkins Lymphoma
  • Leukemia
    • Acute Leukemia
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • MPN-PV-ET-MF
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Non Hodgkins Lymphoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cancer
  • Rectal Cancer
  • Sarcoma
  • Skin Care
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer
  • Triple Negative Breast Cancer
  • Uterine Cancer
  • About Us
  • Advertising
  • News
  • Newly Diagnosed
  • Treatment & Care
  • Survivorship
  • Join the Community
  • Newsletter

Dr. C H Weaver MD

  • GLP-1 Use Linked to Lower Breast Cancer Incidence in One Study
    June 9, 2026

    GLP-1 Use Linked to Lower Breast Cancer Incidence in One Study

    Dr. C H Weaver MD
  • Blood Tests to Track Cancer: Understanding Your ctDNA and Liquid Biopsy Options
    June 4, 2026

    Blood Tests to Track Cancer: Understanding Your ctDNA and Liquid Biopsy Options

    Dr. C H Weaver MD
  • FDA Grants Accelerated Approval to Sonrotoclax (Begalzi) for Relapsed or Refractory Mantle Cell Lymphoma
    June 1, 2026

    FDA Grants Accelerated Approval to Sonrotoclax (Begalzi) for Relapsed or Refractory Mantle Cell Lymphoma

    Dr. C H Weaver MD
  • Ken’s Story: Using ctDNA to Help Navigate Colorectal Cancer Follow-Up
    June 1, 2026

    Ken’s Story: Using ctDNA to Help Navigate Colorectal Cancer Follow-Up

    Dr. C H Weaver MD
  • Ken’s Story: Understanding ctDNA After Colorectal Cancer Surgery
    June 1, 2026

    Ken’s Story: Understanding ctDNA After Colorectal Cancer Surgery

    Dr. C H Weaver MD
  • Kidney Problems in MPNs: An Overlooked Complication
    May 31, 2026

    Kidney Problems in MPNs: An Overlooked Complication

    Dr. C H Weaver MD
  • Imfinzi (Durvalumab) Expands Role in Bladder Cancer With FDA Approvals in Muscle-Invasive and High-Risk Non-Muscle Invasive Disease
    May 31, 2026

    Imfinzi (Durvalumab) Expands Role in Bladder Cancer With FDA Approvals in Muscle-Invasive and High-Risk Non-Muscle Invasive Disease

    Dr. C H Weaver MD
  • FDA Approves Enhertu for Two New Indications in HER2-Positive Early-Stage Breast Cancer
    May 18, 2026

    FDA Approves Enhertu for Two New Indications in HER2-Positive Early-Stage Breast Cancer

    Dr. C H Weaver MD
  • Atezolizumab Plus ctDNA MRD Testing Wins FDA Approval to Improve Outcomes in Muscle-Invasive Bladder Cancer
    May 18, 2026

    Atezolizumab Plus ctDNA MRD Testing Wins FDA Approval to Improve Outcomes in Muscle-Invasive Bladder Cancer

    Dr. C H Weaver MD
  • FDA Approves First All-Oral Combination Option for Certain Patients With Newly Diagnosed AML
    May 15, 2026

    FDA Approves First All-Oral Combination Option for Certain Patients With Newly Diagnosed AML

    Dr. C H Weaver MD
  • When AI Can’t Say “I Don’t Know”
    May 15, 2026

    When AI Can’t Say “I Don’t Know”

    Dr. C H Weaver MD
  • New FDA-Approved Targeted Therapy for ESR1-Mutated Metastatic Breast Cancer
    May 6, 2026

    New FDA-Approved Targeted Therapy for ESR1-Mutated Metastatic Breast Cancer

    Dr. C H Weaver MD
Previous Page
1 2 3 4 5 … 383
Next Page
  • Sitemap
  • About Us
  • Advertising
  • Privacy Policy
Loading Comments...